Hoag researchers have identified a molecular warning signal in the blood that could make it possible to detect ovarian cancer years before a tumor develops. The signal is associated with isolated STIC, a microscopic, non-invasive precursor to ovarian cancer, marking a potentially significant advancement in early detection.

A Korean biotech company has, for the first time globally, elucidated an innovative technology that leverages systemic immune memory to prevent both the recurrence of primary tumors and the onset of secondary cancers of a different type.

This groundbreaking finding has been selected as the front cover article for the November issue of 'Cancer Cell', a world-leading journal in oncology. With an Impact Factor (IF) of 56.1, Cancer Cell holds academic influence on par with renowned scientific journals such as 'Nature' and 'Science'.

MedPacto (CEO Jung-Won Woo), an innovative drug development company, announced these significant achievements based on preclinical studies of its next-generation anti-cancer drug candidate, 'MP010'.

This milestone is expected to heighten global anticipation for the upcoming clinical trials of MP010, scheduled to begin early next year. Furthermore, it is projected to serve as a major turning point for worldwide research into transforming growth factor-beta (TGF-β) inhibitors, which has been actively pursued across the globe.